Achievement of minimal disease activity in psoriatic arthritis according to the time of administration of synthetic disease-modifying antirheumatic drugs, a comparative analysis of the efficacy of oral and subcutaneous methotrexate. Data from the All-Russian Psoriatic Arthritis Registry

Achievement of minimal disease activity in psoriatic arthritis according to the time of administration of synthetic disease-modifying antirheumatic drugs, a comparative analysis of the efficacy of oral and subcutaneous methotrexate. Data from the All-Russian Psoriatic Arthritis Registry

The goal of psoriatic arthritis (PsA) therapy is to achieve remission or minimal disease activity (MDA). According to the EULAR guidelines, synthetic disease-modifying antirheumatic drugs (sDMARDs), methotrexate (MTX) in particular, are first-line therapy for PsA.Objective: to study the rate of MDA...

Full description

Bibliographic Details
Main Authors: T. V. Korotaeva, E. Yu. Loginova, E. E. Gubar, Yu. L. Korsakova, M. V. Sedunova, I. N. Pristavsky, I. N. Kushnir, I. F. Umnova, S. S. Kudishina
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2021-02-01
Series:Современная ревматология
Subjects:
psoriatic arthritis
minimal disease activity
synthetic disease-modifying antirheumatic drugs
methotrexate
Online Access:https://mrj.ima-press.net/mrj/article/view/1096

Internet

https://mrj.ima-press.net/mrj/article/view/1096

Similar Items